209 related articles for article (PubMed ID: 34572811)
1. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study.
Chen YY; Chen CL; Lin CC; Wang CC; Liu YW; Li WF; Chen YH
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572811
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.
Bang K; Casadei-Gardini A; Yoo C; Iavarone M; Ryu MH; Park SR; Kim HD; Yoon YI; Jung DH; Park GC; Ahn CS; Moon DB; Hwang S; Kim KH; Song GW; Mazzarelli C; Alimenti E; Chan SL; De Giorgio M; Ryoo BY; Lee SG
Cancer Med; 2023 Feb; 12(3):2572-2579. PubMed ID: 36812124
[TBL] [Abstract][Full Text] [Related]
3. Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study.
Han B; Ding H; Zhao S; Zhang Y; Wang J; Zhang Y; Gu J
Front Oncol; 2020; 10():562103. PubMed ID: 33365268
[TBL] [Abstract][Full Text] [Related]
4. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.
Yuan W; Yue W; Wen H; Wang X; Wang Q
Eur Surg Res; 2023; 64(2):268-277. PubMed ID: 36812900
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib.
Chen YY; Wang CC; Liu YW; Li WF; Chen YH
PeerJ; 2020; 8():e10382. PubMed ID: 33240675
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
Chen YH; Chen YY; Wang JH; Hung CH
Anticancer Res; 2023 Mar; 43(3):1377-1384. PubMed ID: 36854513
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
Ichida A; Akamatsu N; Nagata R; Mihara Y; Kawaguchi Y; Bae SK; Ishizawa T; Kaneko J; Arita J; Hasegawa K
Anticancer Res; 2022 Feb; 42(2):1161-1167. PubMed ID: 35093921
[TBL] [Abstract][Full Text] [Related]
8. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria.
Guo DZ; Cheng JW; Yan JY; Huang A; Wang YP; Zhang SY; Cao Y; Huang XW; Fan J; Zhou J; Yang XR
Ann Transl Med; 2022 Oct; 10(20):1091. PubMed ID: 36388794
[TBL] [Abstract][Full Text] [Related]
10. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.
Yang Z; Wang S; Tian XY; Xie QF; Zhuang L; Li QY; Chen CZ; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):365-370. PubMed ID: 32553774
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea.
Goh MJ; Oh JH; Park Y; Kim J; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Cancer; 2021 Feb; 10(1):52-62. PubMed ID: 33708639
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis.
Qin HN; Ning Z; Sun R; Jin CX; Guo X; Wang AM; Liu JW
Front Oncol; 2022; 12():1003426. PubMed ID: 36483048
[TBL] [Abstract][Full Text] [Related]
13. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.
Chen J; Xiong P; Nie M; Pan Y; Wang J; Hu D; Zhou Z; Zhang Y; Chen M; Xu L
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2491-2500. PubMed ID: 35752744
[TBL] [Abstract][Full Text] [Related]
14. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.
Lee J; Han JW; Sung PS; Lee SK; Yang H; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Oh JS; Chun HJ; Bae SH; Choi JY; Yoon SK
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575160
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Wang S; Wang Y; Yu J; Wu H; Zhou Y
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428618
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China.
Zhu Y; Sun P; Wang K; Xiao S; Cheng Y; Li X; Wang B; Li J; Yu W; Cheng Y
Cancer Cell Int; 2021 Sep; 21(1):503. PubMed ID: 34537075
[TBL] [Abstract][Full Text] [Related]
18. The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.
Kawamura A; Uojima H; Chuma M; Shao X; Hidaka H; Nakazawa T; Take A; Sakaguchi Y; Numata K; Kako M; Nozaki A; Azuma S; Horio K; Kusano C; Atsuda K
BMC Cancer; 2022 Aug; 22(1):912. PubMed ID: 35999529
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
Piñero F; Thompson M; Marín JI; Silva M
World J Transplant; 2020 Nov; 10(11):297-306. PubMed ID: 33312891
[TBL] [Abstract][Full Text] [Related]
20. Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy.
Li X; Wang J; Ding X; Xu Y; Yu M; Wu H; Deng N; Li W; Chen J
Front Pharmacol; 2022; 13():1032881. PubMed ID: 36703739
[No Abstract] [Full Text] [Related]
[Next] [New Search]
